<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KEDBUMIN- albumin (human) injection, solution </strong><br>Kedrion S.p.A<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use KEDBUMIN™ safely and effectively. See full prescribing information for KEDBUMIN™ [Albumin (Human) U.S.P.] sterile, aqueous solution for single dose intravenous administration<br>Initial U.S. Approval: June, 2011.</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Dosage forms and strenghts (<a href="#JEC03057bd6811-8619-11e0-9d78-0800200c9a66">3</a>) 08/2012 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">KEDBUMIN™ is a 25% albumin solution indicated for: </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span> <a href="#JEC01157bd6811-8619-11e0-9d78-0800200c9a66">(1.1)</a> and <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span> <a href="#JEC01257bd6811-8619-11e0-9d78-0800200c9a66">(1.2)</a>
</li>
<li>Prevention of central <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> after paracentesis due to cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> <a href="#JEC01357bd6811-8619-11e0-9d78-0800200c9a66">(1.3)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian hyperstimulation syndrome</span> (OHSS) <a href="#JEC01457bd6811-8619-11e0-9d78-0800200c9a66">(1.4)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>) <a href="#JEC01557bd6811-8619-11e0-9d78-0800200c9a66">(1.5)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span> <a href="#JEC01657bd6811-8619-11e0-9d78-0800200c9a66">(1.6)</a>
</li>
<li>Hemodialysis patients undergoing long term dialysis <a href="#JEC01757bd6811-8619-11e0-9d78-0800200c9a66">(1.7)</a>
</li>
<li>Patients who cannot tolerate substantial volumes of salt solution <a href="#JEC01757bd6811-8619-11e0-9d78-0800200c9a66">(1.7)</a>
</li>
<li>Priming as part of a cardiopulmonary bypass fluids <a href="#JEC01857bd6811-8619-11e0-9d78-0800200c9a66">(1.8)</a>
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Intravenous Administration Only. KEDBUMIN™ may be diluted with 5% glucose or 0.9% sodium chloride. Concentration, dosage, and infusion-rate should be adjusted to the patient’s individual requirements and indication <a href="#JEC02157bd6811-8619-11e0-9d78-0800200c9a66">(2.1)</a>. Daily dosage should not exceed 2g per kg body weight. </p>
<table>
<tbody class="Headless"><tr class="First Last"><td colspan="2"><span class="Bold">Indication:  Dose</span></td></tr></tbody>
<tbody class="Headless"><tr class="First Last">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span>:</span></td>
<td>Adults: Initial dose of 25 g is suggested.</td>
</tr></tbody>
<tbody class="Headless"><tr class="First Last">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span>: </span></td>
<td>50-75 g</td>
</tr></tbody>
<tbody class="Headless"><tr class="First Last">
<td><span class="Bold">Prevention of<br>Central Volume<br>Depletion after<br>Paracentesis due to<br>Cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span>:</span></td>
<td>Adults: 6-8 g for every 1000 mL of ascitic<br>fluid removed</td>
</tr></tbody>
<tbody class="Headless"><tr class="First Last">
<td><span class="Bold">OHSS:</span></td>
<td>Adults: 50-100 g over 4 hours and repeated<br>at 4-12 hour intervals as necessary.<br>10-50 g;<br>single infusion</td>
</tr></tbody>
<tbody class="Headless"><tr class="First Last">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>:</span></td>
<td>Adults: 25 g over 30 minutes and repeated at 8<br>hours for 3 days if necessary</td>
</tr></tbody>
<tbody class="Headless"><tr class="First Last">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span>:</span></td>
<td>Determined by direct observation of vital signs<br>or measurement of either plasma oncotic<br>pressure or protein content</td>
</tr></tbody>
<tbody class="Headless"><tr class="First Last">
<td><span class="Bold">Hemodialysis:</span></td>
<td>100 mL</td>
</tr></tbody>
<tbody class="Headless"><tr class="First Last">
<td><span class="Bold">Cardiopulmonary Bypass:</span></td>
<td>Estimated from the difference between the<br>desired and actual total serum protein<br>concentration multiplied by the estimated plasma<br>volume (approximately 40mL per kg) times 2</td>
</tr></tbody>
</table>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">KEDBUMIN™ is a sterile, single dose solution containing 0.25 g per mL human albumin in the following presentation: </p>
<ul>
<li>12.5 g albumin per 50 mL single dose vial <a href="#JEC03057bd6811-8619-11e0-9d78-0800200c9a66">(3)</a>
</li>
<li>25 g albumin per 100 mL single dose vial <a href="#JEC03057bd6811-8619-11e0-9d78-0800200c9a66">(3)</a>
</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in the presence of normal or increased intravascular volume <a href="#JEC04057bd6811-8619-11e0-9d78-0800200c9a66">(4)</a>.</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to albumin, the excipients, or components of the container.</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Risk of transmission of infectious agents <a href="#JEC05157bd6811-8619-11e0-9d78-0800200c9a66">(5.1)</a>.</li>
<li>Caution where <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> and its consequences or hemodilution could represent a special risk <a href="#JEC05257bd6811-8619-11e0-9d78-0800200c9a66">(5.2)</a>
</li>
<li>Do not dilute with water for injections <a href="#JEC05257bd6811-8619-11e0-9d78-0800200c9a66">(5.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <a href="#JEC06057bd6811-8619-11e0-9d78-0800200c9a66">(6)</a>. </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact KEDRION at 1-855-427-6378 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: no human or animal data.  Use only if clearly needed <a href="#JEC08157bd6811-8619-11e0-9d78-0800200c9a66">(8.1)</a>.</li>
<li>Pediatric use: ages 12-16 years use as in adults <a href="#JEC08457bd6811-8619-11e0-9d78-0800200c9a66">(8.4)</a>
</li>
</ul></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Prevention of Central <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span> after Paracentesis due to Cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.4 <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian Hyperstimulation Syndrome</span> (OHSS)</a></h2>
<h2><a href="#section-1.5" class="toc">1.5 <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>)</a></h2>
<h2><a href="#section-1.6" class="toc">1.6 <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span></a></h2>
<h2><a href="#section-1.7" class="toc">1.7 Hemodialysis</a></h2>
<h2><a href="#section-1.8" class="toc">1.8 Cardiopulmonary Bypass</a></h2>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Administration </a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4  Large Volumes</a></h2>
<h2><a href="#section-5.5" class="toc">5.5  Hydration</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Infectious Diseases</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 General</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.4  Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">15  REFERENCES</a></h1>
<h1><a href="#section-13" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="SPLSERV-E7BF19AB-4239-0AEF-CE5D-8CA746035CEA"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="JEC01057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC01157bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span></h2>
<p class="First">For restoration and maintenance of circulating blood volume where volume deficiency is demonstrated and colloid use is appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC01257bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span></h2>
<p class="First">KEDBUMIN™ is indicated for severe albumin deficiency caused by illness or active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. When albumin deficiency results from excessive protein loss, the effect of albumin administration will be temporary unless the underlying disorder is reversed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC01357bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Prevention of Central <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span> after Paracentesis due to Cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span></h2>
<p class="First">KEDBUMIN™ is indicated for maintenance of cardiovascular function following the removal of large volumes of ascitic fluid due to cirrhosis <a href="#JEC15057bd6811-8619-11e0-9d78-0800200c9a66">[1, 2]</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC01457bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-1.4"></a><p></p>
<h2>1.4 <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian Hyperstimulation Syndrome</span> (OHSS)</h2>
<p class="First">KEDBUMIN™ is indicated as a plasma expander in the fluid management in of severe forms of <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">ovarian hyperstimulation syndrome</span> (OHSS) <a href="#JEC15057bd6811-8619-11e0-9d78-0800200c9a66">[3, 4]</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC01557bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-1.5"></a><p></p>
<h2>1.5 <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>)</h2>
<p class="First">KEDBUMIN™ is indicated in conjunction with diuretics to correct fluid volume overload associated with <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span> <a href="#JEC15057bd6811-8619-11e0-9d78-0800200c9a66">[5]</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC01657bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-1.6"></a><p></p>
<h2>1.6 <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span></h2>
<p class="First">KEDBUMIN™ is indicated after &gt; 24 hours post burn in patients experiencing severe albumin depletion in order to favor <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> re-absorption <a href="#JEC15057bd6811-8619-11e0-9d78-0800200c9a66">[6]</a>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC01757bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-1.7"></a><p></p>
<h2>1.7 Hemodialysis</h2>
<p class="First">KEDBUMIN™ is indicated in patients undergoing long term dialysis or for those patients who are fluid-overloaded and cannot tolerate substantial volumes of salt solution for therapy of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <a href="#JEC15057bd6811-8619-11e0-9d78-0800200c9a66">[7]</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC01857bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-1.8"></a><p></p>
<h2>1.8 Cardiopulmonary Bypass</h2>
<p class="First">KEDBUMIN™ is indicated in cardiopulmonary bypass procedures as part of the priming fluids <a href="#JEC15057bd6811-8619-11e0-9d78-0800200c9a66">[8, 9]</a>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="JEC02057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Intravenous Administration Only.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC02157bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage</h2>
<p class="First">The concentration of the albumin preparation, dosage, and infusion-rate should be adjusted to the patient’s individual requirements and indication.</p>
<table border="0" cellpadding="4" width="60%">
<colgroup>
<col width="40%">
<col width="60%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Indication</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Dose</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span></span></td>
<td class="Botrule Lrule Rrule Toprule">Adults: Initial dose of 25 g is suggested. Pediatric dosage should be adjusted based upon on age, weight and clinical conditions</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span></span></td>
<td class="Botrule Lrule Rrule Toprule">50-75 g</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Prevention of Central <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span> after<br>Paracentesis due to Cirrhotic <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span></span></td>
<td class="Botrule Lrule Rrule Toprule">Adults: 6-8 g for every 1000 mL of ascitic fluid removed</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">OHSS</span></td>
<td class="Botrule Lrule Rrule Toprule">Adults:50-100 g over 4 hours and repeated at 4-12 hour intervals as necessary. 10-50 g: single infusion</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span></span></td>
<td class="Botrule Lrule Rrule Toprule">Adults: 25 g over 30 minutes and repeated at 8 hours for 3 days if necessary</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span></span></td>
<td class="Botrule Lrule Rrule Toprule">The amount of albumin required to achieve adequate plasma volume and protein content should be determined by direct observation of vital signs or measurement of either plasma oncotic pressure or protein content</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Hemodialysis</span></td>
<td class="Botrule Lrule Rrule Toprule">100 mL</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Cardiopulmonary Bypass</span></td>
<td class="Botrule Lrule Rrule Toprule">Required dose can be estimated from the difference between the desired and actual total serum protein concentration multiplied by the estimated plasma volume (approximately 40mL per kg) times 2 (to account for extravascular deficit, which absorbs about half of the administered dose)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC02257bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Administration </h2>
<p class="First"><span class="Bold">Intravenous administration only.</span></p>
<p>Inspect visually for particulate matter and discoloration prior to administration, whenever the solution and container permit. </p>
<p>Do not dilute with sterile water for injection as <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> may occur <a href="#JEC05357bd6811-8619-11e0-9d78-0800200c9a66">(5.3)</a>.</p>
<p>KEDBUMIN™ may be diluted with 5% glucose or 0.9%  sodium chloride.</p>
<p>Adjust the infusion rate to the rate of removal in plasma exchange.</p>
<p>Warm the product to room temperature if large volumes are to be administered.</p>
<p>Do not begin administration &gt; 4 hours after the container has been entered. Discard unused material. </p>
<p>Record the batch number every time KEDBUMIN™ is administered to a patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="JEC03057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">KEDBUMIN™ is a sterile, aqueous solution for single dose administration intravenously. The product contains 0.25 g per mL human albumin and is available in the following presentation <a href="#JEC15057bd6811-8619-11e0-9d78-0800200c9a66">[10]</a>:</p>
<ul>
<li>12.5 g albumin per 50 mL single dose vial  </li>
<li>25 g albumin per 100 mL single dose vial </li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="JEC04057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">KEDBUMIN™ is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to albumin, excipients used in its formulation, or components of the container <a href="#JEC15057bd6811-8619-11e0-9d78-0800200c9a66">[11]</a>.</p>
<p>KEDBUMIN™ is also contraindicated in severely <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemic</span> patients and in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="JEC05057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC05157bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been observed, and may in some cases progress to severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Epinephrine should be available immediately to treat any acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC05257bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span></h2>
<p class="First">KEDBUMIN™ should be used with caution in conditions where <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> and its consequences or hemodilution could represent a special risk <a href="#JEC10057bd6811-8619-11e0-9d78-0800200c9a66">(10)</a>. Examples of such conditions may include but are not limited to:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span></li>
<li>Arterial <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></li>
<li><span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">Esophageal varices</span></li>
<li><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span></li>
<li><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Hemorrhagic diathesis</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></li>
<li>Renal and post-renal <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC05357bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span></h2>
<p class="First">Do not dilute KEDBUMIN™ with Sterile Water for Injection, as this may cause <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> in recipients. There is a risk of potentially fatal <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> from the use of Sterile Water for Injection as a diluent for 25% albumin<span class="Sup">12</span>. Suitable solutions for dilution include 5% glucose and 0.9% sodium chloride <a href="#JEC02257bd6811-8619-11e0-9d78-0800200c9a66">(2.2)</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC05457bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-5.4"></a><p></p>
<h2>5.4  Large Volumes</h2>
<p class="First">When replacing comparatively large volumes of albumin, control of coagulation and hematocrit is essential. Ensure adequate substitution of other blood constituents as coagulation factors, electrolytes, platelets, and erythrocytes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC05557bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-5.5"></a><p></p>
<h2>5.5  Hydration</h2>
<p class="First">The colloid osmotic effect of KEDBUMIN™ 25% is approximately four times that of human blood. Therefore, when concentrated albumin is administered, ensure adequate hydration of the patient. Carefully monitor to guard against circulatory overload <a href="#JEC10057bd6811-8619-11e0-9d78-0800200c9a66">(10)</a>.</p>
<p>Hemodynamic performance should be monitored regularly. This may include arterial blood pressure and pulse rate, central venous pressure, pulmonary artery occlusion pressure, urine output, electrolyte levels, and hematocrit/hemoglobin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC05657bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Infectious Diseases</h2>
<p class="First">Because KEDBUMIN™ is derived from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases or CJD have ever been identified for KEDBUMIN. </p>
<p>ALL <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Kedrion at 1-855-427-6378.</p>
<p>See also <span class="Bold">PATIENT COUNSELING INFORMATION</span><a href="#JEC17057bd6811-8619-11e0-9d78-0800200c9a66">(17)</a>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="JEC06057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="JEC06157bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-6.1"></a><p></p>
<h2>6.1 General</h2>
<p class="First">The most common adverse reactions include <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. These reactions normally disappear when the infusion rate is slowed or stopped.</p>
<p>If a severe reaction such as <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> occurs, the infusion should be stopped and appropriate treatment initiated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="JEC07057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<p class="First">KEDBUMIN™ should not be mixed with other medicinal products including blood and blood components, but can be administered concomitantly with other parenterals such as whole blood, plasma, saline, glucose or sodium lactate when medically necessary.</p>
<p>KEDBUMIN™ should not be mixed with protein hydrolysates or solutions containing alcohol since these combinations may cause protein precipitation.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="JEC08057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="JEC08157bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First">Pregnancy Category C. Animal reproductive studies using KEDBUMIN™ have not been conducted. It is also not known whether KEDBUMIN™ can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. KEDBUMIN™ should be given to a pregnant woman only if necessary.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="JEC08457bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-8.2"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">The adult dose may be given in children 12-16 years of age. Use of KEDBUMIN™ in children less than 12 years of age has not been clinically evaluated. If administered to children the dosage will vary with the clinical state and body weight of the individual. Typically, a dose one-fourth to one-half the adult dose may be administered. The usual rate of administration in children should be one-fourth the adult rate. Physicians should weigh the risks and benefits of KEDBUMIN™ in the pediatric population.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="JEC10057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span> may occur if the dosage and rate of infusion are too high. At the first clinical sign of circulatory overload, e.g. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, jugular venous congestion, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, raised central venous pressure, or <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, the infusion should be stopped and hemodynamic parameters carefully monitored. Additionally, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> should be increased in accordance with the severity of the clinical situation <a href="#JEC05257bd6811-8619-11e0-9d78-0800200c9a66">(5.2)</a>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="JEC11057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">KEDBUMIN™ is a sterile, aqueous solution for single dose intravenous administration. The product contains 0.25 g per mL human albumin and is prepared by <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> ethanol fractionation from pooled human plasma obtained from venous blood at FDA-licensed facilities located in the USA. Intermediate source material (albumin paste) is obtained from a U.S. licensed manufacturer. The colloid osmotic effect of KEDBUMIN™ is approximately four times that of blood plasma.</p>
<p>KEDBUMIN™ is a clear, slightly viscous liquid, with a yellow, amber, or green tint. The productis stabilized by the addition of 0.08 mmol sodium caprylate and 0.08 mmol sodium acetyltryptophan per gram of albumin. Additionally, each liter of material contains 130-160 mEq of sodium ion and ≤ 200 µg of aluminum. The product contains no preservatives.</p>
<p>KEDBUMIN™ is heated for ten hours at 60°C. The KEDBUMIN manufacturing process results in viral reduction in in vitro studies (see <a href="#SPLSERV-E689DDBE-9933-7ECF-9F1D-FF0F1C84DCD3">table</a> below). These reductions are achieved through a combination of process steps including Cohn fractionation and final container heat treatment.</p>
<table border="0" cellpadding="4" width="80%">
<colgroup>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
</colgroup>
<tfoot><tr class="First Last"><td>HIV-1: Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus Type 1<br>BVDV: Bovine Viral <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhoea</span> Virus<br>PRV: Pseudorabies Virus<br>REO: Reovirus Type 3<br>PPV: Porcine Parvovirus<br>HAV: <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> A Virus<br>EMCV: Encephalomyocarditis virus</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="7"><span class="Bold">Mean Reduction Factor (log10)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Enveloped viruses</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><span class="Bold">Non enveloped viruses</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Manufacturing Step</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">HIV-1</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">BVDV</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">PRV </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">REO</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">PPV</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">HAV</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">EMCV</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Fractionation of Effluent I to Effluent II<br>+III</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Fractionation of Effluent IV-1 to Effluent<br>IV-4</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Ethanol inactication during fraction<br>V precipitation</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&gt;3.71</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">&gt;3.38</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Depth Filtration of Fraction V suspension</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">≥3.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Generation of Albumin paste</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Heat treatment</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">≥6.06</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">&gt;5.17</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&gt;5.07</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4.62</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">&gt;5.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="right"><span class="Bold">Overall Reduction Factor</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">≥16.57</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">&gt;10.17</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">≥15.75</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">11.62</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">5.2</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">&gt;8.4</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">3.7</span></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="JEC12057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="JEC12157bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Human albumin is not a glycoprotein. It has the lowest molecular weight (66,241 Daltons) of all plasma proteins. Because of its three dimensional structure, solutions of albumin have a lower viscosity than solutions of other plasma proteins. This is important since work performed by the heart depends in part on the viscosity of blood. Human albumin accounts quantitatively for more than half of the total proteins in the circulation (by weight) and represents approximately 10 % of the protein synthesized in the liver.</p>
<p>Approximately 40% of albumin is contained in the circulation. The remainder is located in the extravascular space of tissues, principally muscle, skin, and intestine.</p>
<p>KEDBUMIN 25% has a hyperoncotic effect.</p>
<p>A major function of albumin is its role in osmotic regulation. Albumin is responsible for 75% of normal oncotic pressure within the intravascular space <a href="#JEC15057bd6811-8619-11e0-9d78-0800200c9a66">[13, 14]</a>. Other physiological functions include binding and transport of molecules (hormones, enzymes, drugs and toxins); free radical scavenging; hemostatic effects (platelet function inhibition and antithrombotic effects); and capillary membrane permeability <a href="#JEC15057bd6811-8619-11e0-9d78-0800200c9a66">[14]</a>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="JEC12357bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-11.2"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">Under normal conditions, the total exchangeable albumin pool is 4-5 g per kg body weight, of which 40-45% is present intravascularly and 55-60% is in the extravascular space. Increased <span class="product-label-link" type="condition" conceptid="4023793" conceptname="Capillary permeability">capillary permeability</span> will alter albumin kinetics and abnormal distribution may occur in conditions such as severe <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> or <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>.</p>
<p>Under normal conditions, the half-life of albumin is approximately 19 days. The balance between synthesis and breakdown is normally achieved by feed-back regulation. Elimination is predominantly intracellular and due to lysosomal proteases. In healthy subjects, less than 10% of infused albumin leaves the intravascular compartment during the first two hours following infusion. There is considerable individual variation in the effect on plasma volume. In some patients plasma volume can remain elevated for several hours. However, in critically ill patients, albumin can leak out of the vascular space in substantial amounts at an unpredictable rate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="JEC15057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-12"></a><p></p>
<h1>15  REFERENCES</h1>
<ol>
<li>Vermeulen LC, Jr., Ratko TA, Erstad BL, Brecher ME, Matuszewski KA. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. <span class="Italics">Arch Intern Med. </span> Feb 27 1995;155(4):373-379.</li>
<li>Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> treated by paracentesis. <span class="Italics">Gastroenterology.</span> Oct 1996;111(4):1002-1010.</li>
<li>Aboulghar M, Evers JH, Al-Inany H. Intravenous albumin for preventing severe <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">ovarian hyperstimulation syndrome</span>: a Cochrane review. <span class="Italics">Hum Reprod.</span> Dec 2002;17(12):3027-3032.</li>
<li>Medicine PCotASfR. <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian Hyperstimulation Syndrome</span>. <span class="Italics">Fertility and <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span>.</span> 2000;86(5 Suppl 1):S178-S183. .</li>
<li>Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">lung injury</span>. <span class="Italics">Crit Care Med.</span> Aug 2005;33(8):1681-1687.</li>
<li>Manelli JC. [Is albumin administration useful in critical care for burnt patients?]. <span class="Italics">Ann Fr Anesth Reanim.</span> 1996;15(4):507-513.</li>
<li>Tullis JL. Albumin. 2. Guidelines for clinical use. <span class="Italics">JAMA.</span> Jan 31 1977;237(5):460-463 concl.</li>
<li>Schiff P. Albumin-containing plasma volume expanders. <span class="Italics">Aust N Z J Surg.</span> Dec 1977;47(6):783-786.</li>
<li>Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of <span class="product-label-link" type="condition" conceptid="4002836" conceptname="Postoperative hemorrhage">postoperative bleeding</span>. <span class="Italics">Ann Thorac Surg.</span> Aug 2001;72(2):527-533; discussion 534.</li>
<li>Gerety RJ, Aronson DL. Plasma derivatives and <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span>. <span class="Italics">Transfusion.</span>  Sep-Oct 1982;22(5):347-351.</li>
<li>Gellis SS, Neefe JR, et al. Chemical, clinical, and immunological studies on the products of human plasma fractionation; inactivation of the virus of homologous <span class="product-label-link" type="condition" conceptid="4281232" conceptname="Type B viral hepatitis">serum hepatitis</span> in solutions of normal human serum albumin by means of heat. <span class="Italics">J Clin Invest.</span> Mar 1948;27(2):239-244.</li>
<li>Pierce LR, Gaines A, Finlayson JS, Varricchio F, Epstein JS. <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> due to the administration of albumin diluted in sterile water. <span class="Italics">Transfusion.</span> Jan 1999;39(1):110-111.</li>
<li>Doweiko JP, Nompleggi DJ. Role of albumin in human physiology and pathophysiology. <span class="Italics">Jpen.</span> Mar-Apr 1991;15(2):207-211.</li>
<li>Mendez CM, McClain CJ, Marsano LS. Albumin therapy in clinical practice. <span class="Italics">Nutr Clin Pract.</span> Jun 2005;20(3):314-320.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="JEC16057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-13"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">KEDBUMIN™ is supplied as a sterile, aqueous solution for single dose intravenous administration containing 0.25 g per mL human albumin. It is available in the following glass vial size: </p>
<p>50 mL vial 25% (NDC 76179-025-01) is packaged in one carton (NDC 76179-025-02)<br><br>100 mL vial 25% (NDC 76179-025-03) is packaged in one carton (NDC 76179-025-04)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="JEC16157bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Do not use KEDBUMIN™ after the expiration date which is stated on the carton and label after “EXP.? The expiration date refers to the last day of that month.</p>
<p>Do not store above 30°C.</p>
<p>Keep the vial stored in the outer carton in order to protect from light.</p>
<p>Do not freeze.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="JEC17057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-14"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">Inform patients being treated with KEDBUMIN about the potential risks and benefits with its use <a href="#JEC06057bd6811-8619-11e0-9d78-0800200c9a66">(6)</a>. Discontinue immediately if allergic symptoms or cardiocirculatory overload occur (e.g. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, breathing difficulties, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>, increased heart rate).</p>
<p>Inform patients that KEDBUMIN is a derivative of human plasma and may contain infectious agents that cause disease (e.g., viruses, and theoretically, CJD agent). Inform patients that the risk that KEDBUMIN may transmit an infectionious agent has been reduced by screening plasma donors for prior exposure for certain viruses, by testing the donated plasma for certain virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and by inactivating and/or removing certain viruses during manufacturing <a href="#JEC05057bd6811-8619-11e0-9d78-0800200c9a66">(5)</a>.</p>
<p><span class="Bold">Distributed by:</span><br>
							Kedrion Biopharma, Inc.<br>
							Parker Plaza, 400 Kelby Street<br> 
							Fort Lee,  NJ 07024<br>
							United States</p>
<p><span class="Bold">Manufactured by:</span><br>
							Kedrion S.p.A. <br>
							Via Provinciale Loc. Bolognana<br>
							55027  Gallicano (Lucca) <br>
							Italy<br>
							Phone: +39 0583 1969 1<br>
							Fax: +39 0583 1969 981<br>
							U.S. License No. 1851<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="JEC19057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-15"></a><p></p>
<h1>PACKAGE LABEL</h1>
<p class="First"><span class="Bold">ALBUMIN(HUMAN) U.S.P.<br><br>KEDBUMIN 25% 12.5 g 50 mL<br><br>NDC 7617902501<br><br>Rx only<br><br>Precautions:</span> Do not freeze.<br><br><span class="Bold">Instructions:</span> The patient and physician should discuss the risks and benefits before using this product. For information on directions of administration, see the enclosed insert.<br><br><span class="Bold">Contents: <br></span>Each 50 mL contains 12.5 g of Albumin (Human) in aqueous diluent. The solution is hyperoncotic. Sodium range 130-160 milliequivalents per liter. <br><br>Contains no preservative. <br><br>Heat treated at 60° C for 10 hours.<br><br><span class="Bold">Distributed by:</span><br>Kedrion Biopharma, Inc. Parker Plaza, <br>400 Kelby Street Fort Lee, NJ 07024 <br>United States<br><br><span class="Bold">Manufactured by:</span><br>Kedrion S.p.A <br>55027 <br>Bolognana, Gallicano <br>(Lucca) Italy <br><br>U.S. License No.1851<br><br><span class="Bold">Keep the vial in the outer carton in order to protect from light. Store at temperatures not exceeding 30° C. <br>DO NOT USE IF TURBID. DO NOT BEGIN ADMINISTRATION MORE THAN 4 HOURS AFTER THE CONTAINER HAS BEEN ENTERED.<br><br>25%<br><br></span>8096036 - Rev. 02 03/12<br><br>Lot:<br><br>Expiration Date:<br><br>Lot:<br><br>Lot:</p>
<p><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 50 ML VIAL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57bd6811-8619-11e0-9d78-0800200c9a66&amp;name=kedrion-spa-1.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="JEC20057bd6811-8619-11e0-9d78-0800200c9a66"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">NDC 7617902502<br><br>Albumin (Human) U.S.P.<br>KEDBUMIN 25%<br>Solution 12.5 g 50 mL<br><br>Store at temperatures not exceeding 30° C<br><br>KEDRION<br><br>25%<br><br>Rx Only<br><br>Precautions:<br></span>Do not use KEDBUMIN 25% after the expiration date which is stated on the carton and label after “EXP.? The expiration date refers to the last date of that month.<br><br>Do not store above 30°C.<br><br>Keep the vial stored in the outer carton in order to protect from light.<br><br>Do not freeze.<br><br><span class="Bold">Instructions:<br><br></span>The patient and physician should discuss the risks and benefits before using this product. For information on directions of administration, see the enclosed insert.<br><br><span class="Bold">DO NOT USE IF TURBID. <br>DO NOT BEING ADMINISTRATION 4 HOURS AFTER THE CONTAINER HAS BEEN ENTERED.<br><br>Contents:<br><br></span>One 50 mL vial containing Albumin (Human) U.S.P. KEDBUMIN 25% <br><br>Each 50 mL contains 12.5 g of Albumin (Human) in aqueous diluent. <br><br>The solution is hyperoncotic. <br><br>Sodium range 130 – 160 milliequivalents per liter. <br><br>Stabilized with 0.08 millimole sodium caprylate and 0.08 millimole acetyltryptophan per gram of albumin<br><br>Contains no preservative <br>Heat treated at 60°C for 10 hours for viral inactivation<br><br><span class="Bold">Distributed by:</span><br>Kedrion Biopharma, Inc. <br>Parker Plaza, 400 Kelby Street <br>Fort Lee, NJ 07024 <br>United States<span class="Bold"><br><br>Manufactured by:</span><br>Kedrion S.p.A. <br>55027 <br>Bolognana, Gallicano (Lucca) Italy <br><br>U.S. License No. 1851<br><br>Lot <br>Expiration Date:<br><br>55x47x88<br><br>8091354<br><br>Rev. 04 08/13</p>
<div class="Figure"><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 50 ML CARTON" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57bd6811-8619-11e0-9d78-0800200c9a66&amp;name=carton50mL.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KEDBUMIN 		
					</strong><br><span class="contentTableReg">albumin (human) injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76179-025</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALBUMIN (HUMAN)</strong> (ALBUMIN (HUMAN)) </td>
<td class="formItem">ALBUMIN (HUMAN)</td>
<td class="formItem">12.5 g  in 50 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (almost clear and colourless) , GREEN (almost clear and colourless) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76179-025-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76179-025-01</td>
<td class="formItem">50 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:76179-025-04</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:76179-025-03</td>
<td class="formItem">100 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125384</td>
<td class="formItem">09/15/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Kedrion S.p.A
							(339096023)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Kedrion S.p.A</td>
<td class="formItem"></td>
<td class="formItem">339096023</td>
<td class="formItem">MANUFACTURE(76179-025)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>de6ce48a-970a-d0ab-0a84-6ed7644735f2</div>
<div>Set id: 57bd6811-8619-11e0-9d78-0800200c9a66</div>
<div>Version: 9</div>
<div>Effective Time: 20120831</div>
</div>
</div> <div class="DistributorName">Kedrion S.p.A</div></p>
</body></html>
